市场调查报告书

全球泌尿道感染(UTI)治疗药市场 - 成长,趋势,预测(2017年~2022年)

Urinary Tract Infection Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品编码 391459
出版日期 内容资讯 英文 115 Pages
商品交期: 2-3个工作天内
价格
Back to Top
全球泌尿道感染(UTI)治疗药市场 - 成长,趋势,预测(2017年~2022年) Urinary Tract Infection Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日内容资讯: 英文 115 Pages
简介

美国女性的5人有1人罹患泌尿道感染(UTI)。还有2002年中,起因于泌尿道感染的住院数量报告是150万件。

本报告提供全球泌尿道感染(UTI)治疗药市场相关调查,市场概要,各治疗类型、症状、地区的市场趋势,市场规模的变化与预测,市场成长、阻碍因素以及市场机会分析,市场占有率,竞争情形,主要企业的简介等,全面性资讯。

目录

第1章 简介

  • 调查的成果
  • 市场定义
  • 调查对象期间及预测
  • 一般调查的前提条件
  • 报告概要

第2章 调查方法

  • 简介
  • 分析方法
  • 调查的时间轴
  • 调查的阶段
    • 2次调查
    • 讨论指南
    • 市场工程&计量经济学模式

第3章 摘要整理

第4章 主要推论

第5章 市场及产业的趋势

  • 目前市场方案
  • 波特的五力分析
    • 买方议价能力
    • 供给企业谈判力
    • 新加入业者的威胁
    • 替代品的威胁
    • 竞争企业间的敌对关系

第6章 市场动态

  • 市场成长要素
    • 发病率高和诊断的正确性
    • 复合治疗药
    • 成药的适应症
  • 市场阻碍因素
    • 低价格的学名药的竞争激烈化
  • 市场机会
  • 主要课题

第7章 全球泌尿道感染(UTI)治疗药市场

  • 各治疗药类型
    • 青霉素 & 复合治疗药
    • 奎诺酮类抗生素(Quinolones)类
    • 头孢菌素
    • Aminoglycosides抗体
    • 磺胺类药物
    • Azoles & Amphotericin B
    • 四环霉素
    • 硝基馅饼
    • 其他
  • 各症状
    • 复杂性UTI
    • 复发性复杂性UTI
    • 非复杂性UTI
    • 神经原因性膀胱

第8章 全球泌尿道感染(UTI)治疗药市场:各地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英语
    • 法国
    • 义大利
    • 西班牙、葡萄牙
    • 斯堪地那维亚各国
    • 荷比卢三国
    • 其他
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲、纽西兰
    • 韩国
    • 其他
  • 中东、非洲
    • 波灣合作理事会(GCC)
    • 南非
    • 其他
  • 南美
    • 巴西
    • 阿根廷
    • 其他

第9章 竞争情形

  • M&A分析
  • 新产品的销售
  • 协定,合作,伙伴关系

第10章 企业简介

  • Pfizer
  • Boehringer Ingelheim
  • Bayer
  • GlaxoSmithKline
  • Novartis
  • Hoffman-La Roche
  • Johnson & Johnson
  • AstraZeneca
  • Cipla
  • Cubist Pharmaceuticals
  • Osel Inc
  • Novexel
  • MerLion Pharmaceuticals
  • 其他

第11章 分析师的投资机会预测

第12章 市场未来展望

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: 46354

The market is expected to witness a CAGR of 3.5% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs.

  • According to the World Health Organization (WHO), in 1980, around 108 million people had diabetes, and this number increased to 422 million in 2014, while the prevalence of diabetes in adults increased from 4.7%, in 1980, to 8.5%, in 2014. This trend of increment in diabetes prevalence rate among adults is expected to continue during the forecast period. Therefore, with the increasing prevalence of diabetes, the number of cases of urinary tract infection (UTI) increases, which in turn, increases the demand for drugs; thus, driving the global urinary tract infection therapeutics market.
  • Additionally, the launch of more efficient combination drugs and increasing geriatric population are expected to boost the growth of the urinary tract infection therapeutics market.
  • However, according to the Center for Education & Research on Therapeutics, over 2 million cases of adverse drug reactions (ADRs) are reported every year, leading to approximately 100,000 deaths.
  • According to the FDA, it is estimated that, in the United States, each year, over 350,000 ADRs occur in nursing homes alone.
  • With an increase in the number of cases of ADRs being reported, globally, there is an awareness among the population about the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
  • Additionally, the lack of awareness about the prevalence of UTIs in the developing and underdeveloped countries is also restraining the growth of the market.

Key Market Trends

Complicated UTIs are Expected to Show Lucrative Growth in the Indication Segment

The prevalence of uncomplicated UTI is significantly higher, as compared to recurring complicated UTI. However, the prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases. Overall, the prevalence of complicated UTI is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and rise in recurrence rate for UTI.

North America Dominates the Market and is Expected to do the Same in the Forecast Period

The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. In addition to that, the CDC, in collaboration with other organizations, developed guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States.

Competitive Landscape

The urinary tract infection therapeutics market is highly competitive and consists of a number of major players. Companies, like AstraZeneca, Bayer AG, Cipla Inc., GlaxoSmithKline PLC, Merlion Pharma, Novartis AG, and Pfizer, among others, hold the substantial share of the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Diabetes and Kidney Stones
    • 4.2.2 Launch of Combination Drugs
  • 4.3 Market Restraints
    • 4.3.1 Adverse Effects Associated with the Use of Medication
    • 4.3.2 Lack of Awareness in the Developing and Underdeveloped Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Penicillin and Combinations
    • 5.1.2 Quinolones
    • 5.1.3 Cephalosporin
    • 5.1.4 Azoles and Amphotericin B
    • 5.1.5 Nitrofurans
    • 5.1.6 Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)
  • 5.2 Indication
    • 5.2.1 Complicated UTI
    • 5.2.2 Uncomplicated UTI
    • 5.2.3 Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca
    • 6.1.2 Bayer AG
    • 6.1.3 Cipla Inc.
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Merlion Pharma
    • 6.1.6 Novartis AG
    • 6.1.7 Pfizer

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top